Baird raises argenx stock price target to $861 on Vyvgart sales

argenx SE (ARGNF) reported a 54% surge in VYVGART sales. The company increased 2026 OpEx guidance to $4B, with half attributed to the Forte acquisition. Management expects growth in MG and CIDP revenues, with additional indications driving Vision 2030. Potential 2027 launches include MMN, pending positive IMPASSION data. The FDA requested an additional dermatomyositis trial, and management remains confident in delivering Vision 2030.

Jefferies reiterated a Buy rating and $1,200 price target for argenx SE (ARGX) after its Q3 results. The company reported Vyvgart revenues of $1.7B, a 5% beat, and EPS of $7.80, in line with estimates. Operating expenses were higher due to the Forte deal. Analysts expect data readouts and revenue growth to drive future performance, with projections of $6.5B in FY2026 revenues. Other analysts have mixed price target adjustments.

argenx (ARGX) reported Q3 earnings, highlighting growth in VYVGART sales for MG and CIDP. The company expanded seronegative label coverage and submitted applications for pediatric and ocular MG. It plans up to five U.S. launches in 2027, including potential MG label expansions, IMNM, an auto-injector, and a possible MMN launch for empasiprubart. Pipeline updates include positive Phase II results for FB-102 in celiac disease and advancements in other programs.

Stifel reduced its price target for argenx (NASDAQ:ARGX) to $1,200 from $1,282, citing mixed Q3 2026 results. Vyvgart sales beat estimates, but a Sjogren’s trial was discontinued. The company reported 70% revenue growth over the last year. Analysts remain bullish on its pipeline, with price targets ranging from $823 to $1,356.

argenx reported Q3 2026 revenue of $1.721B, up 54% YoY, exceeding expectations. The company plans up to 5 launches in 2027, expanding into rheumatology and gastroenterology. Cash position is $3.7B, with strong profitability and growth investments.

argenx reported Q3 2026 revenue of $1.56B, beating estimates by $90M, but EPS of $6.95 missed forecasts by $0.07. Revenue grew 54% YoY, driven by strong U.S. sales and product net sales of $1.7B. The company expects five potential launches in 2027. The stock was little changed, trading at $787.2, up 0.08%.